A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer

This is a prospective, single-arm, multi-center Phase II clinical trial designed to evaluate the efficacy and safety of neoadjuvant therapy with SHR-A1811 in combination with Adebelimumab in patients with resectable, early-stage non-small cell lung cancer (NSCLC) harboring HER2 alterations.

NCT Number	NCT07281209
Lead Sponsor	Shanghai Chest Hospital
Conditions	NSCLC
Enrollment	40 participants
Start Date	2025-12
Primary Completion	2027-12 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2025-12-15